New advances in microsphere-based single-dose vaccines.
暂无分享,去创建一个
Langer | Cleland | Hanes | J. Hanes | Robert Langer | Jeffrey L. Cleland
[1] Michael J. Pikal,et al. Freeze‐Drying of Proteins. Process, Formulation, and Stability. , 1995 .
[2] F. Vogel,et al. A compendium of vaccine adjuvants and excipients. , 1995, Pharmaceutical biotechnology.
[3] D. Ruble,et al. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres , 1995, Infection and immunity.
[4] R. N. Brogden,et al. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. , 1994, Drugs.
[5] S. Wharton,et al. Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. , 1993, Vaccine.
[6] K. Mills,et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.
[7] Rajesh K. Gupta,et al. Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.
[8] J. Hunt,et al. Radiation damage to crystalline ribonuclease: identification of polypeptide chain breakage in the denatured and aggregated products. , 1967, Radiation research.
[9] A. Gettie,et al. Protection against vaginal SIV transmission with microencapsulated vaccine. , 1993, Science.
[10] R. Langer,et al. Controlled release of polypeptides from polyanhydrides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. G. Pitt,et al. Poly (glycolic acid-co-dl-lactic acid): diffusion or degradation controlled drug delivery? , 1992 .
[12] J. Eldridge,et al. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. , 1989, Advances in experimental medicine and biology.
[13] M. Helliwell. The use of bioadhesives in targeted delivery within the gastrointestinal tract , 1993 .
[14] R. Langer,et al. Synthesis and Characterization of Degradable Anhydride-co-imide Terpolymers Containing Trimellitylimido-l-tyrosine: Novel Polymers for Drug Delivery , 1996 .
[15] D. Rahman,et al. Biodegradable microparticles for oral immunization. , 1993, Vaccine.
[16] P. Felgner,et al. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[17] H. Sah,et al. Continuous release of proteins from biodegradable microcapsules and in vivo evaluation of their potential as a vaccine adjuvant , 1995 .
[18] J. Cantey,et al. Specific adherence of Escherichia coli (strain RDEC-1) to membranous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit. , 1983, The Journal of clinical investigation.
[19] J. Hunt,et al. Radiation damage to crystalline ribonuclease: importance of free radicals in the formation of denatured and aggregated products. , 1967, Radiation research.
[20] J L Cleland,et al. Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. , 1996, Journal of pharmaceutical sciences.
[21] E. Gilboa,et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.
[22] T. Kissel,et al. INJECTABLE BIODEGRADABLE MICROSPHERES FOR VACCINE DELIVERY , 1996 .
[23] M. Powell,et al. Immunological and formulation design considerations for subunit vaccines. , 1995, Pharmaceutical biotechnology.
[24] W. Cray,et al. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. , 1986, The Journal of infectious diseases.
[25] K. Rock,et al. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. , 1996, Journal of immunology.
[26] R. Finberg,et al. Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. , 1983, Gastroenterology.
[27] D. Pardoll. Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.
[28] B. Gander,et al. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. , 1995, Vaccine.
[29] O. Böstman,et al. Absorbable pins of self-reinforced poly-L-lactic acid for fixation of fractures and osteotomies. , 1992, The Journal of bone and joint surgery. British volume.
[30] D. Crommelin,et al. Controlled release of bioactive agents from lactide/glycolide polymers , 1990 .
[31] H. Sah,et al. Degradability and antigen‐release characteristics of polyester microspheres prepared from polymer blends , 1995 .
[32] R. Langer,et al. Biodegradable polymers as drug delivery systems , 1990 .
[33] R. Langer,et al. Drug release from a new family of biodegradable polyanhydrides , 1994 .
[34] R. Langer,et al. The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[35] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[36] S. Kohbata,et al. Cytopathogenic Effect of Salmonella typhi GIFU 10007 on M cells of Murine Ileal Peyer's Patches in Ligated Ileal Loops: An Ultrastructural Study , 1986, Microbiology and immunology.
[37] R. Rappuoli,et al. Absence of protective immunity against diphtheria in a large proportion of young adults. , 1993, Vaccine.
[38] R. Langer,et al. Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. , 1997, Biomaterials.
[39] S. H. Leung,et al. Binding of acrylic polymers to mucin/epithelial surfaces: structure-property relationships. , 1988, Critical reviews in therapeutic drug carrier systems.
[40] G. Winde,et al. Clinical and functional results of abdominal rectopexy with absorbable mesh-graft for treatment of complete rectal prolapse. , 1993, The European journal of surgery = Acta chirurgica.
[41] R. H. Bruce,et al. Low vaccination levels of US preschool and school-age children. Retrospective assessments of vaccination coverage, 1991-1992. , 1994, JAMA.
[42] E. Jaffee,et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.
[43] A. Klibanov,et al. Stability of Proteins and Their Delivery from Biodegradable Polymer Microspheres , 1996 .
[44] M. Powell,et al. Vaccine Design , 1995, Pharmaceutical Biotechnology.
[45] R Langer,et al. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. , 1985, Journal of biomedical materials research.
[46] T. Wrin,et al. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. , 1996, Journal of pharmaceutical sciences.
[47] M. Buggy,et al. Irradiation of poly-D,L-lactide , 1992 .
[48] T. Arakawa,et al. Interactions of Stabilizers with Proteins During Freezing and Drying. , 1995 .
[49] G. Gregoriadis. Immunological adjuvants: a role for liposomes. , 1990, Immunology today.
[50] R. Gupta,et al. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[51] D. O'hagan,et al. Intestinal translocation of particulates — implications for drug and antigen delivery , 1990 .
[52] J L Cleland,et al. Protein delivery from biodegradable microspheres. , 1997, Pharmaceutical biotechnology.
[53] W. Koff,et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. , 1997, Vaccine.
[54] A. Shahzamani,et al. In vivo characterization of sustained-release formulations of human growth hormone. , 1997, The Journal of pharmacology and experimental therapeutics.
[55] D. O’hagan. Novel Delivery Systems for Oral Vaccines , 1994 .
[56] R. Martuza,et al. Treatment of glioma by engineered interleukin 4-secreting cells. , 1993, Cancer research.
[57] R. Langer,et al. Poly(anhydride) administration in high doses in vivo: studies of biocompatibility and toxicology. , 1990, Journal of biomedical materials research.
[58] J. Kraehenbuhl,et al. Transepithelial transport and mucosal defence I: the role of M cells. , 1992, Trends in cell biology.
[59] J. Cleland. Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. , 1995, Pharmaceutical biotechnology.
[60] E. Jaffee,et al. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[61] J. Freund. The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. , 1951, American journal of clinical pathology.
[62] A. Shahzamani,et al. A month–long effect from a single injection of microencapsulated human growth hormone , 1996, Nature Medicine.
[63] J. Mcghee,et al. Biodegradable microspheres as a vaccine delivery system. , 1991, Molecular immunology.
[64] J C Murphy,et al. Single-step immunization using a controlled release, biodegradable polymer with sustained adjuvant activity. , 1986, Journal of immunological methods.
[65] R. Langer,et al. Degradation of porous poly(anhydride-co-imide) microspheres and implications for controlled macromolecule delivery. , 1998, Biomaterials.
[66] P. Lambert,et al. Controlled-release vaccines--biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. , 1992, Immunobiology.
[67] D. Keren,et al. Role of M cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis , 1989, Infection and immunity.
[68] J. Benoit,et al. In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. , 1989, Biomaterials.
[69] K. Rock,et al. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[70] Michael Wolff,et al. The influence of terminal gamma-sterilization on captopril containing poly(d,l-lactide-co-glycolide) microspheres , 1994 .
[71] C. Kensil,et al. Structural and immunological characterization of the vaccine adjuvant QS-21. , 1995, Pharmaceutical biotechnology.
[72] R. Langer,et al. Formulation and Delivery of Proteins and Peptides. Design and Development Strategies. , 1995 .
[73] I. Horáček,et al. Influence of molecular weight on the resistance of polylactide fibers by radiation sterilization , 1993 .
[74] J L Cleland,et al. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. , 1993, Critical reviews in therapeutic drug carrier systems.
[75] R. Daum,et al. Accuracy of immunization histories provided by adults accompanying preschool children to a pediatric emergency department. , 1993, JAMA.
[76] K. Rock,et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity , 1995, Nature Medicine.
[77] R K Gupta,et al. Pulsed controlled-released system for potential use in vaccine delivery. , 1996, Journal of pharmaceutical sciences.
[78] T. Kissel,et al. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. , 1992, Vaccine.
[79] J L Cleland,et al. Development of a single-shot subunit vaccine for HIV-1. , 1997, AIDS research and human retroviruses.
[80] N Lotan,et al. Large porous particles for pulmonary drug delivery. , 1997, Science.
[81] C. Alving. Delivery of liposome-encapsulated drugs to macrophages. , 1983, Pharmacology & therapeutics.
[82] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[83] B. Bloom. Vaccines for the Third World , 1989, Nature.
[84] R. Gupta,et al. Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen. , 1996, Journal of pharmaceutical sciences.
[85] S. Arya. Human immunization in developing countries: practical and theoretical problems and prospects. , 1994, Vaccine.
[86] Thomas R. Tice,et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .
[87] S. Rosenberg,et al. Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.
[88] R. Langer,et al. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. , 1997, Journal of pharmaceutical sciences.
[89] J. Tamada,et al. The development of polyanhydrides for drug delivery applications. , 1992, Journal of biomaterials science. Polymer edition.
[90] R. Gupta,et al. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. , 1994, Vaccine.
[91] G. Ada. Strategies for exploiting the immune system in the design of vaccines. , 1991, Molecular immunology.
[92] D. Rahman,et al. Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.
[93] M. Aguado. Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. , 1993, Vaccine.
[94] Brooks M. Boyd,et al. Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect , 1997 .
[95] G. Stollerman,et al. The measles epidemic. The problems, barriers, and recommendations. The National Vaccine Advisory Committee. , 1991, JAMA.
[96] Noah Lotan,et al. Large porous aerosols for pulmonary drug delivery , 1997 .
[97] V. Stevens,et al. Vaccine Delivery Systems: Potential Methods for Use in Antifertility Vaccines , 1993, American journal of reproductive immunology.
[98] D. Pardoll,et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.
[99] W. Linehan,et al. Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.
[100] Y. Ikada,et al. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. , 1988, Journal of biomedical materials research.
[101] P. Leder,et al. Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.
[102] Robert Langer,et al. Polymerization Reactions Involving the Side Chains of α-L-Amino Acids , 1987 .
[103] R. Langer,et al. Polymer microspheres for vaccine delivery. , 1995, Pharmaceutical biotechnology.
[104] R. Zhuo,et al. Synthesis and Biological Properties of Polymer Immunoadjuvants , 1993 .
[105] X M Li,et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. , 1996, Vaccine.
[106] J. Fox,et al. Evaluation of ethylene-vinyl acetate copolymer as a non-inflammatory alternative to Freund's complete adjuvant in rabbits. , 1985, Laboratory animal science.
[107] W. Wooden,et al. Subcuticular sutures and the rate of inflammation in noncontaminated wounds. , 1995, Annals of emergency medicine.
[108] R. Langer,et al. A single-step immunization by sustained antigen release. , 1979, Journal of immunological methods.
[109] N. Jacobsen,et al. Isomerization and formulation stability of the vaccine adjuvant QS-21. , 1996, Journal of pharmaceutical sciences.
[110] J. Warchoł,et al. Poliovirus type 1 enters the human host through intestinal M cells. , 1990, Gastroenterology.